2322 results about "Cardiac muscle" patented technology

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving one or more vascular models associated with either the patient or with a plurality of individuals; receiving observed perfusion information associated with the patient; and estimating, using one or more computer processors, one or more blood flow characteristics or one or more pathological characteristics of the patient based on the observed perfusion information and the one or more vascular models.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

Various systems, devices, and methods are disclosed herein for treating acute myocardial infarction (AMI) patients using a heart pump controlled in a manner that maximizes mechanical unloading of the left ventricle in the presence of cardiovascular instability and minimizes myocardial oxygen consumption (MVO2) and consequentially infarct size to prevent the development of subsequent heart failure. In a closed feedback system, the system can include a sensor configured to generate an output used to measure or calculate a left ventricular systolic pressure (LSVP) within the left ventricle of a heart and a controller coupled to a heart pump. The controller can be configured to measure or calculate the LVSP based on the output of the sensor and to control an operation of the heart pump to maximize mechanical unloading of the left ventricle based on the measured or calculated LVSP.

Systems and methods for four-dimensional analysis of a patient's coronary arteries and myocardial wall. An example method includes accessing angiographic x-ray images of one or more arteries, with the x-ray images depicting the arteries from respective angles, with each x-ray image being associated with a cardiac phase of cardiac phases, and with the cardiac phases being included in a cardiac cycle. A three-dimensional model of the arteries is generated for each cardiac phase based on a subset of the x-ray images which are associated with the cardiac phase. A four-dimensional representation of the arteries is generated throughout the cardiac cycle based on the three-dimensional models for the cardiac phase. Information associated with the four-dimensional presentation is presented.

Systems and methods are disclosed for to determining a blood supply and blood demand. One method includes receiving a patient-specific model of vessel geometry of at least a portion of a coronary artery, wherein the model is based on patient-specific image data of at least a portion of a patient's heart having myocardium; determining a coronary blood supply based on the patient-specific model; determining at least a portion of the myocardium corresponding to the coronary artery; determining a myocardial blood demand based on either a mass or a volume of the portion of the myocardium, or based on perfusion imaging of the portion of the myocardium; and determining a relationship between the coronary blood supply and the myocardial blood demand.

The invention proposes a myocardial magnetic resonance image fibrosis classification method based on a convolutional neural network, and relates to the technical field of image processing, and the method comprises the steps: obtaining an original magnetic resonance image of a to-be-detected target from a magnetic resonance imaging device, and carrying out the preprocessing of the original magnetic resonance image; segmenting the preprocessed magnetic resonance image into a plurality of sub-regions based on the connected features, each sub-region representing an independent connected part in the image; constructing a gray scale measurement function for each sub-region, quantifying the gray scale distribution characteristics of each sub-region, and identifying the sub-region with the minimum gray scale measurement function value as a fibrosis tissue sub-region by comparing the gray scale measurement function values of the sub-regions; features are extracted from the identified fibrosis tissue sub-regions to serve as input of the convolutional neural network model, the fibrosis tissue sub-regions are classified, the fibrosis stages to which the fibrosis tissue sub-regions belong are output, and the accuracy of classification of the fibrosis tissue is improved.

The invention relates to a myocardial injury risk assessment method and device, computer equipment and a storage medium. The method comprises the following steps: acquiring and analyzing a resting electrocardiosignal to obtain a high-frequency QRS envelope curve and a resting low-frequency electrocardiosignal; analyzing the high-frequency QRS envelope curve to obtain a resting high-frequency QRS feature including a resting positive lead number, a resting critical lead number, a first target lead number, a second target lead number, a third target lead number and a high-frequency form index; the first target lead number refers to a lead number of which the wave crest number is greater than or equal to a first number threshold; the second target lead number refers to the lead number with the wave crest number equal to the second number threshold value; the third target lead number refers to the number of leads of which the crest number is equal to a third number threshold; the resting low-frequency electrocardiosignals are analyzed to obtain resting low-frequency characteristics such as old myocardial infarction information; and analyzing the myocardial injury risk assessment feature set comprising the resting high-frequency QRS feature and the resting low-frequency feature to obtain a myocardial injury risk assessment score.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The invention relates to a preparation method of Pt monatomic nano-enzyme and application of Pt monatomic nano-enzyme in cardiac troponin I. The preparation method comprises the following steps: 1) ultrasonically dispersing cobalt salt, selenium powder, chloroplatinic acid, urea and sodium chloride in an alcohol solvent, heating and stirring until the solvent is completely volatilized to obtain a solid mixture, and grinding the solid mixture into powder; and 2) placing the powder in a heating device, carrying out Joule heat treatment in an air atmosphere, washing a reactant, and carrying out vacuum drying to obtain the Pt monatomic nano-enzyme. Se doping is introduced in the one-step chemical reaction process to construct oxygen vacancies, rapid heating and structural shaping are achieved in combination with Joule heat treatment, the Se-doped Co3O4-loaded Pt monatomic catalyst is obtained, the oxygen vacancies and Se doping sites are synergistically used as anchoring sites, Pt monatomic atoms are effectively fixed, and the loading capacity and dispersity of the Pt monatomic atoms are improved. The obtained material shows excellent POD-like enzyme activity, can be used for constructing a high-sensitivity colorimetric immunoassay system, and realizes rapid and accurate detection of cTnI.

The invention relates to the technical field of physiological signal prediction, in particular to a preoperative risk assessment method for the department of cardiology, which comprises the following steps: sliding window segmentation time sequence data to calculate a baseline offset, dynamic time warping alignment parameter fluctuation rate to generate an abnormal mark, and standard deviation comparison amplitude threshold triggering risk signals. K-means clustering multi-dimensional data mapping risk levels, isolated forest detection abnormal fluctuation and electrocardiogram and myocardial zymogram cross validation are combined, and a preoperative risk assessment conclusion is output. According to the method, individual differences and interferences are eliminated through a sliding window algorithm, a time difference problem is solved by aligning a multi-parameter fluctuation rate through dynamic time warping, a quantitative evaluation standard is established by comparing a standard deviation with an amplitude threshold value to avoid limitation of a single threshold value, and objective grading is realized by combining K-means clustering with an Euclidean distance. The isolated forest algorithm, the electrocardiogram ST segment and myocardial zymogram cross validation form a multi-modal evaluation system, and the risk evaluation sensitivity and specificity are improved in a complete closed-loop mode.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The disclosure provides various embodiments of systems to facilitate the cutting of myocardial tissue structures percutaneously.

The invention provides a clinical diagnosis and treatment path generation method and system for tracking a chest pain patient. Wherein a dynamic spatio-temporal data atlas is constructed by synchronously collecting respiratory rhythm phase difference, coronary artery calcification integral and hypersensitive troponin curve slope, and risk degree transition signals are generated by coupling analysis of ST segment elevation amplitude asymmetric growth, left ventricular ejection fraction attenuation gradient and B-type natriuretic peptide release rate. In the acute stage, the constraint relation between a vascular recanalization time window and thrombolysis taboo is dynamically bound, in the subacute stage, a phase synchronization rule for enhancing CT scanning and anticoagulant drug dosage is established through a multidisciplinary interface, intravascular ultrasonic plaque morphological mutation characteristics and extracorporeal circulation parameters are fused, the blood supply reconstruction time sequence is dynamically adjusted based on a myocardial oxygen consumption balance equation, and the thrombolysis time sequence is determined. And path self-optimization is realized through space-time superposition of an interventional therapy delay parameter and a drug metabolism curve. According to the technical scheme provided by the invention, chest pain diagnosis and treatment path dynamic optimization and multi-modal parameter collaborative decision-making are realized, and the risk layering precision and the treatment timeliness are improved.

The present application provides a cardiac fibrosis diagnosis model based on multi-task attentional feature fusion. The cardiac fibrosis diagnosis model is established by the following steps: S01: image collection and labeling: obtaining cardiac magnetic resonance (MR) images as sample data, and performing manual labeling to obtain heart labels corresponding to the MR images; S02: image preprocessing, including normalization processing, data enhancement, and data clipping; S03: model establishment, including establishment of an image recovery network and establishment of an image segmentation and classification network, and executing an image recovery task; S04: model pre-training: training the image recovery network such that the encoder of the image recovery network fully learns the feature of the cardiac fibrosis image; and S05: model training. An objective of the present application is to improve the segmentation precision and diagnosis accuracy of a network model for a cardiac fibrosis image.

The invention relates to the field of gene therapy, in particular to an RBM25 gene epigenetics activation technology based on a CRISPR / dCas9-SunTag system and application of the RBM25 gene epigenetics activation technology in ischemic heart failure treatment, the RBM25 gene epigenetics activation technology comprises the following steps: (a) protein containing inactivated Cas9 (dCas9) fused with a plurality of GCN4 peptide repetitive sequences, the number of the GCN4 peptide repetitive sequences is 8-12, and the dCas9 contains D10A and H840A double mutations; (b) a protein containing fusion of an anti-GCN4 single-chain antibody fragment (scFv) and a TET1 catalytic structural domain; (c) at least one gRNA of a target RBM25 gene promoter region, wherein a target sequence of the gRNA is selected from a sequence as shown in SEQ ID NO: 1-3; and (d) a lipid nanoparticle (LNP) system for delivery of said (a), (b), and (c).

The invention relates to the field of biomedical materials, discloses a hydrogen sulfide / nitric oxide synergistic anti-inflammatory and anti-coagulation repair promoting coating as well as a preparation method and application thereof, and provides a coating with anti-inflammatory, anti-coagulation and tissue repair promoting functions through the synergistic effect of hydrogen sulfide and nitric oxide. The coating comprises a hydrogen sulfide donor which can spontaneously release hydrogen sulfide or a precursor thereof or release hydrogen sulfide under external stimulation; the coating further comprises a component capable of catalyzing the release of nitric oxide from the endogenous nitric oxide donor. The coating is covalently connected with the surface of a base material through a chemical means to form firm interface bonding; and the coating has a multi-cross-linked network structure, so that the coating is endowed with good stability, and long-term functional application of the coating on the surface of a biomedical material is ensured. The method can be widely applied to surface modification of biomedical materials, especially coating functionalization of implanted instruments such as valve clips, intravascular stents, heart valves, occluders, vascular grafts and myocardial patches.

The invention relates to the technical field of medical image analysis, in particular to a left ventricular compliance assessment method and system based on medical image.The method comprises the following steps that a planar three-dimensional coordinate from a left ventricular apex to a mitral annulus is obtained through a CT image, a thin-plate spline interpolation algorithm is called to establish a left ventricular long-axis model, the ultrasonic end-stage internal diameter is obtained synchronously, and a left ventricular compliance assessment result is obtained. And inputting the left greenhouse long axis model and the ultrasonic diastole end-stage inner diameter into an Euclidean distance calculation function to generate a left greenhouse length-diameter ratio. According to the method, a left greenhouse long axis model is constructed by integrating CT three-dimensional coordinates and ultrasonic inner diameter, the length-diameter ratio is calculated by combining Euclidean distance, point cloud registration is carried out, a myocardial wall area is segmented, local deformation is quantized by utilizing Gaussian curvature gradient, a correction factor is generated by inputting a radial basis function network, and a parameter coupling mechanism is established by fusing an aorta root angle. And optimizing the weight of the pressure-volume equation, establishing a dynamic model, and realizing a quantitative evaluation system of spatial heterogeneity and time continuity.

The invention relates to the technical field of spermidine application, in particular to application of spermidine in preparation of medicine for preventing and treating doxorubicin-induced cardiotoxicity and myocardial aging. Cell proliferation experiments and mouse survival rate experiments show that spermidine can reduce death of myocardial cells and mice caused by adriamycin; a q-PCR experiment shows that spermidine can improve abnormal expression conditions of P53, P21, P16, BAX, TNF-alpha, IFN alpha, IL-10 and IL-18 in myocardial cells caused by adriamycin; a beta-galactosidase staining experiment shows that the spermidine can reduce the condition that the expression of a marker beta-galactosidase for myocardial cell senescence induced by adriamycin is increased; a Western Blot experiment shows that the spermidine can improve the condition that the P53 protein is abnormally increased due to the adriamycin; an Elisa experiment shows that spermidine can improve the condition that myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin, and the myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin. Therefore, spermidine can improve cardiotoxicity and myocardial aging induced by adriamycin.

Devices and systems as described herein is configured to sense a signal, such as a signal from an individual. In some embodiments, a signal is a magnetic field. In some embodiments, a source of a signal is an individual's organ, such as a heart muscle. A device or system, in some embodiments, comprises one or more sensors, such as an array of sensors configured to sense the signal. A device or system, in some embodiments, comprises a shield or portion thereof to reduce noise and enhance signal collection.

The invention discloses a hypertensive heart disease early screening system fusing ultrasonic multiple parameters, which comprises the following steps: acquiring ultrasonic image data and physiological index monitoring parameters of a patient at different time points, performing difference comparison on heart structure parameters to generate time sequence change data, and establishing a multi-dimensional data fusion scheme based on the time sequence change data and physiological indexes; according to the fusion scheme, acute risk trigger factors are identified, blood flow abnormal parameters are generated, and emergency threshold comparison is carried out to generate acute risk early warning signals; extracting a myocardial strain degradation rate to determine a chronic degradation acceleration time point, carrying out disease progress stage association to generate a chronic risk layering curve, and establishing a clinical index comparison table; carrying out double-layer correlation on the acute risk early warning signal and the chronic risk layering curve, and carrying out calibration judgment to generate a comprehensive risk judgment sequence; the sequence is decomposed into an acute judgment layer and a chronic judgment layer, a risk threshold value is configured to generate an instant early warning signal, a layered screening report is formed, and technical support is provided for early discovery of the hypertensive heart disease.

The invention discloses a compound composition with a multi-target heart protection function as well as a preparation method and application of the compound composition. The composition is composed of a basic functional oil phase, a core antioxidant / anti-inflammatory phase, a myocardial nutrition and regulation phase and a bioavailability promotion phase in a synergistic manner, and is integrated into a composite cardiac oligopeptide and microencapsulated particle key component substance through a specific enzymolysis and microencapsulation embedding process system. The invention aims to solve the technical problems of single target spot, insufficient synergistic effect of all components, low bioavailability of active components and poor stability of the existing heart protection product, and provides a stable and easily-absorbed composite composition which can realize synergistic effect from multiple channels at the same time. Technical effect verification shows that under the condition of equal-dose sample feeding, the composition can remarkably improve the bioavailability of functional components and shows excellent myocardial cell oxidative damage resistance and myocardial ischemia improvement activity in cell and animal models, the effect is remarkably superior to that of independent use or simple physical mixing of all the components, and the composition is suitable for clinical application. And the substantial progress of synergistic interaction is proved. The composition can be used for developing various medicines, health foods and functional foods beneficial to heart health.

The invention provides a bionic flexible force sensor based on a tenon-and-mortise structure and a high-performance medical patch material, belongs to the technical field of biomedical engineering, and can be used for multiple organ tissues such as myocardium and skin. The bionic flexible force sensor is provided with an upper base and a lower base; the upper base and the lower base are of a concave-convex interlocking tenon-and-mortise structure. A plurality of convex tenons are designed on the bottom surface of the upper base, a plurality of concave mortises corresponding to the tenons are designed on the top surface of the lower base, and the tenons and the mortises are precisely matched to form stable locking; the tenons and the mortises are connected through buckle structures, and sliding and loosening are prevented. The bionic flexible force sensor is integrated and fixed on the surface or inside the medical patch through a micro-adhesion technology. A renewable wood-based enhanced visible light 3D printing technology is adopted, and nanofibers, nanocrystals and composite nanoparticles are combined, so that the patch material has excellent mechanical properties, electrical conductivity and drug controlled release property.

Devices, systems and methods deliver implantable medical devices for atrioventricular (VfA) cardiac treatment. The VfA device can be implanted in the right atrium (RA), where electrodes extend from the right atrium into the left ventricular myocardium. A flexible lead or other probe can be advanced to a potential implantation site and used to identify the precise location of an implanted medical device, such as an electrode, a small lead, a lead, or an intracardiac device. Some methods may include locating a potential implantation site in the Koch triangle in the right atrium of the patient's heart; attaching a retaining sheath to the right atrial endocardium of the potential implantation site; and implanting the medical device via a guidewire at the potential implantation site. An implantable medical device may include an intracardiac housing and a small lead that can be delivered by these methods.

The invention discloses a heart image processing method and device, a storage medium and computer equipment, and relates to the technical field of nuclear medicine image processing and quantitative analysis. The method comprises the steps that a heart image to be processed is acquired, four cavities of the heart image are segmented based on a pre-trained segmentation model, segmentation masks are obtained, and the heart image is a CT image or an MR image; aligning the heart image into a PET space, so that the segmentation mask is mapped to a PET image corresponding to the heart image, and a PET segmentation image is obtained; and cutting the PET segmented image based on the segmentation mask to obtain a PET target anatomical region, and performing three-dimensional rendering on the PET target anatomical region to obtain a dynamic rendered image of tracer agent distribution. According to the method, the segmentation precision of the myocardial subregion can be improved, and the three-dimensional visualization effect of the heart image and the processing efficiency of the heart image are improved.

The utility model discloses a cardiac muscle patch with a microneedle for cardiac bypass, which comprises a patch main body used for being adhered and wrapped on the surface of a vein bridge blood vessel in a cardiac bypass operation; the plurality of microneedles are uniformly distributed on the adhesive surface of the patch main body, and drug particles are attached to the surfaces of the microneedles; and the reinforced connection structures are uniformly distributed on the surface of the patch main body, are connected to the interiors of the microneedles, and are used for reinforcing the connection between the microneedles and the patch main body. According to the myocardial patch with the micro-needle for heart bypass, the surface of the patch is combined with the hydrogel micro-needle to form an integrated structure, so that loaded drugs, such as antiplatelet tirofiban sustained-release particles, are loaded to the needle body of the micro-needle, and continuous and stable release of the tirofiban sustained-release particles can be ensured; the myocardial patch is directionally conveyed to a vein bridge area, so that simple and convenient application of the myocardial patch in a vein bridge is facilitated.

The invention relates to the technical field of medical data analysis, in particular to a sepsis prediction system based on deep learning. The system comprises a sepsis risk assessment module, a capillary barrier injury analysis module, a myocardial inhibition analysis module and a sepsis prediction module, and blood lactic acid concentration data of a patient are obtained through a lactic acid analyzer; acquiring oxygenation state data of a patient through a blood gas analyzer, and performing sepsis risk assessment according to the oxygenation state data of the patient and the blood lactic acid concentration data of the patient, so as to obtain sepsis risk data; obtaining a lung structure image through a high-resolution chest CT; performing alveolar feature extraction according to the lung structure image to obtain alveolar data; according to the pulmonary alveolar data, capillary barrier injury analysis is carried out, so that capillary barrier injury data is obtained; an echocardiogram is obtained by an echocardiograph. The sepsis prediction accuracy is improved based on a medical data analysis technology.

The invention discloses a high-sensitivity cardiac troponin-T electrochemiluminescence detection kit. The kit comprises a magnetic microsphere reagent coated by a high-sensitivity cardiac troponin-T capture antibody and a high-sensitivity cardiac troponin-T detection antibody reagent labeled by an electrically neutral ruthenium compound, the structural general formula of the electrically neutral ruthenium compound is # imgabs0 # n = 0-9; the magnetic microsphere reagent coated with the high-sensitivity cardiac troponin-T capture antibody comprises a magnetic microsphere coated with the high-sensitivity cardiac troponin-T capture antibody and a diluent; the electrically neutral ruthenium compound labeled high-sensitivity cardiac troponin-T detection antibody reagent comprises an electrically neutral ruthenium compound labeled high-sensitivity cardiac troponin-T detection antibody and a diluent; the diluent is prepared from piperazine-1, 4-diethyl sulfonic acid or 3-(N-morpholinyl)-2-hydroxy propanesulfonic acid. When the high-sensitivity cardiac troponin-T electrochemiluminescence detection kit is used for detection, a reaction system does not contain streptavidin coated magnetic beads or biotinylated antibodies, so that interference of biotin in a sample is avoided.

The invention belongs to the field of biological medicines, and particularly discloses application of DNAJB6 in preparation of medicines for preventing or treating myocardial infarction (MI). In-vivo and in-vitro experiments find that the expression of DNAJB6 protein in an MI model is remarkably reduced, and the over-expression of DNAJB6 can improve the cardiac function of a mouse after MI, relieve myocardial fibrosis and inhibit hypoxia-induced myocardial apoptosis; and cell apoptosis is aggravated by low expression of DNAJB6. The overexpression of the DNAJB6 by using the myocardial specific adeno-associated virus (AAV) can be used as a new strategy for preventing and treating the MI, and an experimental basis is provided for developing a drug for targeting the DNAJB6.

The wire comprises an insulating layer, an electrode tip assembly and an anchoring component, the electrode tip assembly comprises an operating part and an electrode tip, the electrode tip is arranged at the far end of the operating part, and the electrode tip assembly can move between a first position and a second position relative to the insulating layer; the electrode tip assembly at the first position is located in the insulating layer, the electrode tip of the electrode tip assembly at the second position extends out of the insulating layer, the surface of the electrode tip is not smooth, and the area of the minimum cross section of the electrode tip is 4.0 mm < 2 >. According to the lead for pace-making, the electrode tip is provided with the non-smooth surface, so that the electrode tip can be slowly inserted into ventricular septal myocardial tissue even if a conical structure is not adopted, and is easy to screw in. The arrangement can ensure that the cross section is not similar to a conical structure and has a small-area cross section, the cross section is not easy to break when being inserted into heart tissue, and the cross section area is small, so that the damage to normal myocardium when the lead is pulled out is small.

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.